Theracurmin® efficiently inhibits the growth of human prostate and bladder cancer cells via induction of apoptotic cell death and cell cycle arrest.

In the present study, we aimed to investigate the anticancer properties of Theracurmin®, a novel form of the yellow curry pigment curcumin, as well as explore the molecular mechanisms of the potential anticancer effects of Theracurmin® on human prostate cancer and bladder cancer cells in vitro.

The proliferation of cancer cells was examined by using the Cell Counting Kit-8. The clonogenic growth potential was determined by clonogenic assay. Cell cycle distribution was evaluated by flow cytometry using propidium iodide staining. Western blot analysis was applied to explore the expression patterns of molecules associated with apoptotic cell death and cell cycle checkpoint. We noted that Theracurmin® and curcumin exhibited similar anticancer effects in both androgen-dependent and -independent human prostate cancer cells in a dose- and time-dependent manner. These agents reduced cell viability and clonogenic growth potential by inducing apoptosis and cell cycle disturbance in human prostate cancer cells. Theracurmin® and curcumin also exerted marked anticancer effects on human bladder cancer cells, even in cisplatin-resistant T24R2 cells, in a dose- and time-dependent manner. Moreover, Theracurmin® and curcumin treatment decreased cell viability and clonogenicity via induction of apoptotic cell death and cell cycle dysregulation in human bladder cancer cells. In conclusion, our study suggests that Theracurmin® has potential as an anticancer agent in complementary and alternative medicine for these urological cancers.

Oncology reports. 2015 Dec 29 [Epub ahead of print]

Minyong Kang, Jin-Nyoung Ho, Ha Rim Kook, Sangchul Lee, Jong Jin Oh, Sung Kyu Hong, Sang Eun Lee, Seok-Soo Byun

Department of Urology, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do 463-707, Republic of Korea. , Department of Urology, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do 463-707, Republic of Korea. , Department of Urology, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do 463-707, Republic of Korea. , Department of Urology, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do 463-707, Republic of Korea. , Department of Urology, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do 463-707, Republic of Korea. , Department of Urology, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do 463-707, Republic of Korea. , Department of Urology, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do 463-707, Republic of Korea. , Department of Urology, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do 463-707, Republic of Korea.

PubMed

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe